Spectranetics Corporation Finalizes EXCITE ISR Adjunct Analysis Plan

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

COLORADO SPRINGS, Colo., May 6, 2013 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today announced the Food and Drug Administration's (FDA) approval of its adjunct analysis plan associated with the EXCITE ISR clinical trial, studying the treatment of in-stent restenosis (ISR) in the legs. The goal of the adjunct analysis plan is to demonstrate statistically significant clinical superiority of laser atherectomy plus balloon angioplasty (PTA) compared with PTA alone, prior to full enrollment of the EXCITE ISR study.

Help employers find you! Check out all the jobs and post your resume.

Back to news